Bubble: Phase 1B Study of buparlisib with Bortezomib in Defined Genetic Subgroups of Patients with Relapsed or Refractory Multiple Myeloma

Trial Overview and Summary

A plain English summary of this trial can be found at on the Cancer Help website (see Other Websites below for the link)

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Trial summary [.pdf]

Chief Investigator: Professor Kwee Yong   
Sponsor: The University of Birmingham   
Funders: Bloodwise (TAP)  
Disease Site: Multiple Myeloma   
Trial Type: Clinical Trial of an Investigational Medicinal Product  
Status: Open   
UKCRN Study ID: 18609  
Open to new sites? Yes  
Recruitment start date:  23-Jun-2016  
Anticipated Recruitment end date: 2019  
CRCTU Trial Management Team: Haematology   
Trial E-mail Address: Bubble@trials.bham.ac.uk  

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

Trial Documents [opens a new page]

More Information